The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2
- 1 January 1994
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (3), 329-333
- https://doi.org/10.1016/0959-8049(94)90251-8
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced CancerJNCI Journal of the National Cancer Institute, 1993
- Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2Annals of Oncology, 1992
- Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinomaEuropean Journal Of Cancer, 1992
- Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.Journal of Clinical Oncology, 1990
- Phase II Trial of High-Dose Intermittent Interleukin-2 in Metastatic Renal Cell Carcinoma: A Southwest Oncology Group StudyJNCI Journal of the National Cancer Institute, 1990
- Recombinant Leukocyte Interferon Alpha-2A and Medroxyprogesterone in Advanced Renal Cell Carcinoma: A Randomized TrialActa Oncologica, 1990
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Treatment of Advanced Renal Cell Carcinoma—Traditional Methods and Innovative ApproachesJournal of Urology, 1983
- The Natural History of Metastatic Renal Cell Carcinoma: A Computer AnalysisJournal of Urology, 1978